{"contentid": 488511, "importid": NaN, "name": "Gilead shares hit as sales figures miss estimates", "introduction": "US biotech major Gilead Sciences was trading 1% lower after an hour\u00e2\u0080\u0099s trading on Friday following the presentation of its first quarter financial results.", "content": "<p>US biotech major Gilead Sciences (Nasdaq: GILD) was trading 1% lower after an hour&rsquo;s trading on Friday following the presentation of its first quarter 2021 financial results.</p>\n<p>The Californian company reported first-quarter earnings of $1.7 billion, or $1.37 a share, compared with $1.5 billion, or $1.23 a share, in the first quarter of 2020.</p>\n<p>Adjusted for one-time items, earnings per share were $2.08, a 24% jump.</p>\n<p>Revenue increased by 16% to $6.4 billion, primarily due to sales of the COVID-19 antiviral drug Veklury (remdesivir), the company said.</p>\n<p>Analysts on average expected adjusted earnings of $2.08 per share on sales of $6.74 billion, according to FactSet.</p>\n<h2>Pivotal year ahead</h2>\n<p>Daniel O&rsquo;Day, chairman and chief executive of Gilead, said: &ldquo;We have made strong progress in this first quarter, with our new partnership with Merck (NYSE: MRK) in long-acting HIV therapies, two newly-approved indications in the USA for Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer and metastatic urothelial cancer, and the addition of Hepcludex (bulevirtide) to our portfolio.</p>\n<p>&ldquo;2021 is a pivotal year for Gilead, with key milestones across our virology and oncology portfolios. We&rsquo;re looking forward to advancing our pipeline of promising therapies in the coming months.&rdquo;</p>\n<p>Except for earnings per diluted share using generally accepted accounting principles, there is no change to the guidance that Gilead shared in February.</p>\n<h2>Selected product sales</h2>\n<p>Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide): $1.82 billion, up 8%</p>\n<p>Veklury: $1.46 billion</p>\n<p>Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide): $673 million, down 18%</p>\n<p>Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide): $367 million, down 10%</p>\n<p>Descovy (emtricitabine/tenofovir): $359 million, down 22%</p>\n<p>&nbsp;</p>", "date": "2021-04-30 15:18:00", "meta_title": NaN, "meta_keywords": "Gilead, trading, billion, sales, quarter, share, earnings, shares, estimates, figures, Sciences, major, presentation, biotech, Friday, results, financial", "meta_description": "US biotech major Gilead Sciences was trading more than 1% lower after an hour\u00e2\u0080\u0099s trading on Friday following the presentation of its first quarter financial resu", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-30 15:08:23", "updated": "2021-05-01 14:08:32", "access": NaN, "url": "https://www.thepharmaletter.com/article/gilead-shares-hit-as-sales-figures-miss-estimates", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "gilead-sciences-logo.gif", "image2id": "gilead-sciences-logo-300x200.gif", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-virals, Infectious diseases, Nephrology and Hepatology", "topic_tag": "Financial, Management", "geography_tag": "USA", "company_tag": "Gilead Sciences", "drug_tag": "Biktarvy, Descovy, Genvoya, Odefsey, Veklury", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-30 15:18:00"}